Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer

Kang, Ho Won; Seo, Sung Pil; Jeong, Pildu; Ha, Yun‐Sok; Kim, Dong-Won; Kim, Yong‐June; Lee, Sang‐Cheol; Yun, Seok‐Joong; Kim, Wun‐Jae

doi:10.3892/ol.2017.6408

Cited by 8 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, no patient with NMIBC in the goodprognosis signature group has experienced cancer progression. The classifier has been validated in patients with an extended follow-up, demonstrating that it is an independent predictor of the development of invasive tumors [36]. This gene classifier could be useful for NMIBC patients who are deciding between surgery and active surveillance (Table 2).…”

Section: Biomarkers In Multiple Gene Classifiersmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer

Cimadamore

Gasparrini

Santoni

et al. 2018

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Over the last decade, the improvement in molecular techniques and the acquisition of genomic information has transformed and increased the quality of patient care and our knowledge of diseases. Areas covered: Protein expression levels in immunohistochemistry and molecular biomarkers are reported for their ability to predict recurrence, progression, development of metastases, or patient survival. In particular, for renal cell carcinoma, we take into consideration the biomarkers applicable to immunohistochemistry and with molecular and genetic analyses. In urothelial carcinoma, there is great interest in the possibility of distinguishing the basal vs. luminal subtypes and to acquire deeper insight into the tumor biology through examining exosomes in urine and biomarkers in the serum. In prostate cancer, single gene expression and multiple gene expression classifiers are reviewed as a tool to distinguish indolent vs. aggressive disease. Expert commentary: The genomic information along with the application of ancillary techniques allow the definition of a neoplasia not only by its morphology but also by its biological signature. This continuous increase in knowledge will result in a better comprehension of oncogenesis, development of targeted therapies and optimizing decision-making processes related to patient care.

show abstract

Section: Biomarkers In Multiple Gene Classifiersmentioning

confidence: 99%

“…Independent predictor of development of invasive tumor[35,36] Urinary markers15 invasion-associated miRNAs in exosomesDegree of invasiveness of bladder cancer[28] Serum markersUroplakins III High serum uroplakin III levels were associated with muscle-invasive status, high grade, lymph vascular invasion, and cancer-specific mortality [29] KLF5, ZFHX3 and CDH1…”

mentioning

confidence: 99%

Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer

Cimadamore

Gasparrini

Santoni

et al. 2018

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

“…Here, based on the immune-associated genes in the ImmPort database, we used the TCGA dataset and a microarray dataset GSE13507 [ 13 , 14 ] to establish and verify signatures of 37 IRGPs targeting bladder cancer patients. Then, the risk score was used to predict the prognosis of bladder cancer.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Implications of Immune-Related Gene Pairs Signatures in Bladder Cancer

Xiong

Gao

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

Compelling evidence indicates that immune function is correlated with the prognosis of bladder cancer (BC). Here, we aimed to develop a clinically translatable immune-related gene pairs (IRGPs) prognostic signature to estimate the overall survival (OS) of bladder cancer. From the 251 prognostic-related IRGPs, 37 prognostic-related IRGPs were identified using LASSO regression. We identified IRGPs with the potential to be prognostic markers. The established risk scores divided BC patients into high and low risk score groups, and the survival analysis showed that risk score was related to OS in the TCGA-training set ( p < 0.001 ; HR = 7.5 [5.3, 10]). ROC curve analysis showed that the AUC for the 1-year, 3-year, and 5-year follow-up was 0.820, 0.883, and 0.879, respectively. The model was verified in the TCGA-testing set and external dataset GSE13507. Multivariate analysis showed that risk score was an independent prognostic predictor in patients with BC. In addition, significant differences were found in gene mutations, copy number variations, and gene expression levels in patients with BC between the high and low risk score groups. Gene set enrichment analysis showed that, in the high-risk score group, multiple immune-related pathways were inhibited, and multiple mesenchymal phenotype-related pathways were activated. Immune infiltration analysis revealed that immune cells associated with poor prognosis of BC were upregulated in the high-risk score group, whereas immune cells associated with a better prognosis of BC were downregulated in the high-risk score group. Other immunoregulatory genes were also differentially expressed between high and low risk score groups. A 37 IRGPs-based risk score signature is presented in this study. This signature can efficiently classify BC patients into high and low risk score groups. This signature can be exploited to select high-risk BC patients for more targeted treatment.

show abstract

“…Cancer biomarkers (including protein, RNA, miRNA, and DNA) not only enable the accurate diagnosis of tumors with early stage but also strengthen the monitoring of tumor recurrence and progression. − To date, various candidate bladder cancer biomarkers have been identified as biomarkers that occur at high rates in pooled UCB, such as apolipoprotein A1 protein (ApoA1), apolipoprotein A2 protein (ApoA2), bladder tumor antigen, and nuclear matrix protein 22, , and various biosensors have been developed to detect biomarkers, such as colorimetric biosensors, fluorescent biosensors, and electrochemical biosensors. − However, these biosensing platforms are limited in point-of-care (POC) testing by the requirement of bulky and expensive analytical instruments, which are not easy to handle. Additionally, the abovementioned proteins are the biomarkers for UCB only that could not be used to identify UTUC.…”

mentioning

confidence: 99%

Instrument-Free Detection of FXYD3 Using Vial-Based Immunosensor for Earlier and Faster Urothelial Carcinoma Diagnosis

Hsu

Yang

et al. 2020

ACS Sens.

View full text Add to dashboard Cite

The incidence and 5 year recurrence rate of urothelial carcinomas (UCs), including UC of the bladder (UCB) and upper urinary tract UC (UTUC), have increased annually. There is a great need for a simple and fast point-of-care (POC) test for early diagnosis and amelioration in the survival rate. We present a POC test comprising a new vial-immunosensor, nanoenzyme, and iPhone 7 plus, which detects and quantifies the new biomarker FXYD domain-containing ion transport regulator 3 (FXYD3) in human urine for specific UC screening, tumor-grade classification, and postoperative monitoring by the grayscale value of the photograph taken. The performance of the proposed POC test was then verified using urine from 4 healthy people, 40 UCB patients (10 patients were low-grade and 30 patients were high-grade), and 13 UTUC patients (2 patients were low-grade and 11 patients were high-grade), confirming the accuracy and specificity by comparing the results with those obtained by enzyme-linked immunosorbent assay (ELISA). Moreover, we also designed a correction method that can make the grayscale values calculated by different smartphones close to the values calculated by iPhone 7 plus, resulting in the POC test enabling simple, fast, universal, and portable testing, data storage, and sharing for personal UCs screening and postoperative monitoring.

show abstract

Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer

Cited by 8 publications

References 22 publications

Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer

Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer

Prognostic Implications of Immune-Related Gene Pairs Signatures in Bladder Cancer

Instrument-Free Detection of FXYD3 Using Vial-Based Immunosensor for Earlier and Faster Urothelial Carcinoma Diagnosis

Contact Info

Product

Resources

About